Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Lazarus

Showing results (361-370 of 434) with videos related to

Pageof 44
Sort By:
The Lancet Regional Health. Europe|July 17, 2025
A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitisJeffrey V Lazarus, Paul N Brennan, Henry E Mark, et al.
Journal of Hepatology|September 24, 2020
A global investment framework for the elimination of hepatitis BJessica Howell, Alisa Pedrana, Sophia E Schroeder, et al.
Nature Reviews. Gastroenterology & Hepatology|January 30, 2026
Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver diseaseJeffrey V Lazarus, Christopher J Kopka, Aina Nicolàs, et al.
Scientific Reports|December 18, 2021
Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry reviewCamila A Picchio, Sabela Lens, Manuel Hernandez-Guerra, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' PerspectiveZobair M Younossi, Homie Razavi, Michael Sherman, et al.
Clinics in Liver Disease|April 6, 2023
Research Priorities for Precision Medicine in NAFLDPaula Iruzubieta, Ramon Bataller, María Teresa Arias-Loste, et al.
The Lancet. Gastroenterology & Hepatology|February 17, 2024
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictionsAlison D Marshall, Alex R Willing, Abe Kairouz, et al.
The Lancet. Gastroenterology & Hepatology|July 31, 2020
Global hepatitis C elimination: an investment frameworkAlisa Pedrana, Jessica Howell, Nick Scott, et al.
AIDS (London, England)|December 8, 2022
The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in EuropeAmanda Mocroft, Adam Geressu, Charles Beguelin, et al.
Southern African Journal of HIV Medicine|September 14, 2022
COVID-19 vaccine acceptance and associated factors among people living with HIV in the Middle East and North Africa regionRahma Mohamed, Trenton M White, Jeffrey V Lazarus, et al.
Pageof 44

Showing results (361-370 of 434) with videos related to

Sort By:
Pageof 44
The Lancet Regional Health. Europe|July 17, 2025
A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitisJeffrey V Lazarus, Paul N Brennan, Henry E Mark, et al.
Journal of Hepatology|September 24, 2020
A global investment framework for the elimination of hepatitis BJessica Howell, Alisa Pedrana, Sophia E Schroeder, et al.
Nature Reviews. Gastroenterology & Hepatology|January 30, 2026
Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver diseaseJeffrey V Lazarus, Christopher J Kopka, Aina Nicolàs, et al.
Scientific Reports|December 18, 2021
Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry reviewCamila A Picchio, Sabela Lens, Manuel Hernandez-Guerra, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' PerspectiveZobair M Younossi, Homie Razavi, Michael Sherman, et al.
Clinics in Liver Disease|April 6, 2023
Research Priorities for Precision Medicine in NAFLDPaula Iruzubieta, Ramon Bataller, María Teresa Arias-Loste, et al.
The Lancet. Gastroenterology & Hepatology|February 17, 2024
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictionsAlison D Marshall, Alex R Willing, Abe Kairouz, et al.
The Lancet. Gastroenterology & Hepatology|July 31, 2020
Global hepatitis C elimination: an investment frameworkAlisa Pedrana, Jessica Howell, Nick Scott, et al.
AIDS (London, England)|December 8, 2022
The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in EuropeAmanda Mocroft, Adam Geressu, Charles Beguelin, et al.
Southern African Journal of HIV Medicine|September 14, 2022
COVID-19 vaccine acceptance and associated factors among people living with HIV in the Middle East and North Africa regionRahma Mohamed, Trenton M White, Jeffrey V Lazarus, et al.
Pageof 44